Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Angiogenic and inflammatory biomarkers for screening and follow-up in patients with pulmonary arterial hypertension

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Sex influences DNA methylation and gene expression in human skeletal muscle myoblasts and myotubes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Adipogenesis in Primary Cell Culture

    Research output: Chapter in Book/Report/Conference proceedingBook chapterResearchpeer-review

  3. Gamma-Aminobutyric Acid Signaling in Brown Adipose Tissue Promotes Systemic Metabolic Derangement in Obesity

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: To identify circulating angiogenic and inflammatory biomarkers with potential in screening for pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc), and in early diagnosis and determination of treatment response in PAH.

METHOD: Plasma samples were taken at the time of PAH diagnosis and at treatment follow-up after a median (interquartile range) of 4 months (3-9.8 months) in idiopathic (n = 9) and SSc-associated PAH (n = 11). In patients with SSc-associated PAH, plasma samples had also been gathered a median of 2 years (0.8-3 years) before PAH diagnosis (n = 10). Additional plasma samples were retrieved at two time-points separated by a median of 12 years (10-13 years) from SSc patients who did not develop PAH (n = 10) and from controls (n = 8). Angiogenic and inflammatory biomarkers were analysed by multiplex immunoassays.

RESULTS: Plasma levels of placenta growth factor (PlGF), soluble vascular endothelial growth factor receptor-1 (sVEGFR-1), and tumour necrosis factor-α (TNF-α) were higher (p < 0.05) in SSc patients who later developed PAH than in those who did not. Plasma vascular endothelial growth factor (VEGF)-D increased (p < 0.05) in SSc patients as PAH developed. Plasma levels of PlGF, VEGF-A, VEGF-D, sVEGFR-1, interleukin-6, and TNF-α were higher (p < 0.05) in PAH than controls. There were no significant differences in circulating biomarkers between idiopathic and SSc-associated PAH. Plasma sVEGFR-1 decreased (p < 0.05) after initiating PAH-targeted treatments.

CONCLUSIONS: Plasma levels of PlGF, sVEGFR-1, TNF-α, and VEGF-D have potential in screening for SSc-associated PAH. Plasma sVEGFR-1 may be a biomarker of treatment response.

Original languageEnglish
JournalScandinavian Journal of Rheumatology
Issue number4
Pages (from-to)319-324
Number of pages6
Publication statusPublished - Jul 2018

    Research areas

  • Aftercare, Aged, Biomarkers, Case-Control Studies, Female, Humans, Hypertension, Pulmonary/blood, Inflammation/immunology, Interleukin-6/immunology, Male, Mass Screening, Middle Aged, Natriuretic Peptide, Brain/blood, Neovascularization, Pathologic/blood, Peptide Fragments/blood, Placenta Growth Factor/blood, Scleroderma, Systemic/blood, Tumor Necrosis Factor-alpha/immunology, Vascular Endothelial Growth Factor A/blood, Vascular Endothelial Growth Factor D/blood, Vascular Endothelial Growth Factor Receptor-1/blood, Vascular Resistance, Walk Test

ID: 56586255